Antitumor Effect of Low Molecular Weight Heparin in Localised Lung Cancer A Phase III Clinical Trial.
Fiche publication
Date publication
septembre 2018
Journal
The European respiratory journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel, Dr PREVOST Alain, Pr WESTEEL Virginie
Tous les auteurs :
Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P
Lien Pubmed
Résumé
The antitumor and antimetastatic properties of heparins have not been tested in patients with early-stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated. Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg once a day for 12 weeks or no treatment on top of standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival (OS). In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean age was 61.6±8.9 years, 190 (34.6%) patients had stage II-III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in OS between groups (Hazard Ratio [HR], 1.24 [95% CI, 0.92-1.68]; p=0.17). There was no difference in the cumulative incidence of recurrence between groups (subdistribution HR [SHR], 0.94 [95% CI, 0.68-1.30]; p=0.70). Adjuvant tinzaparin had no detectable impact on overall and recurrence-free survival of patients with completely resected stage I-IIIA NSCLC. These results do not support further clinical evaluation of LMWHs as antitumor agents.: ClinicalTrials.gov identifier NCT00475098, first received: May 16, 2007.
Référence
Eur. Respir. J.. 2018 Sep 27;: